Advertisement
MIRA 外匯新聞
Mira Pharmaceuticals Steps Closer To Ketamir-2 IND Submission After Positive Preclinical Results
Pharmaceutical company MIRA Pharmaceuticals, Inc. (MIRA) said Tuesday it is conducting pre-clinical studies of Ketamir-2 in collaboration with Frontage Laboratories as a potential treatment for individuals battling treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDSI) and post-traumatic stress disorder (PTSD).
RTTNews
|
496天前
MIRA Pharmaceuticals Partners Pharmaseed To Conduct Pre-Clinical Studies On Ketamir
MIRA Pharmaceuticals, Inc. (MIRA) on Monday announced a partnership with Pharmaseed Ltd., a clinical research organization or CRO, to research and evaluate Ketamir-2, a novel ketamine analog with improved gastrointestinal bioavailability under investigation to potentially be an orally delivered ultra-rapid antidepressant.
RTTNews
|
553天前
